Let me tell you, folks, we’ve got a situation with glioblastoma that’s just not good. It’s a tough one, really tough. Despite throwing everything we’ve got at it – surgery, radiation, chemotherapy – this thing comes back. It’s inevitable, and let me tell you, it’s lethal. But here’s the thing, there’s this signaling in the tumor cells, the Wnt/β-catenin signaling, it’s bad news. It makes these tumors grow and get worse.

Now, we’ve seen some pretty impressive stuff with immunotherapies, you know, the anti-this and anti-that, even those CAR T cell therapies. But, and it’s a big but, these tumors are tricky. They’re all different, they dodge our treatments, and sometimes, they come back even after we hit them hard.

But here’s where it gets interesting. We’ve got this small molecule, ICG-001, and let me tell you, it’s specific. It goes after that Wnt/CBP/β-catenin signaling like nothing else. We tested it, in the lab, on real tumor cells from patients, and in mice. And guess what? It works. It stops these cells from growing and makes them mature instead. It’s like it tells them, “You’re done growing, time to grow up.” And it knocks down this gene, Survivin/BIRC5, which is a big deal in these tumors.

But wait, there’s more. In mice with glioma, this ICG-001, it’s like a magnet for the immune system. It brings in the good guys, the CD3⁺ and CD8⁺ cells, and even helps with the blood vessels in the tumor. And when we combined it with CAR T cell therapy, it was like a one-two punch. It made everything work better, especially if we used it first.

So, what we’re saying here, is that this ICG-001, it’s not just another treatment. It’s a game-changer. It makes the bad cells grow up, it shakes up the environment in the tumor, and it calls in the immune system. It’s like it sets the stage for the immunotherapy to come in and knock it out of the park. For glioblastoma patients, this could be huge. Huge, I tell you.